A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

Phase 1/2 Active not recruiting 32 enrolled Octant, Inc.

RandomizedSequentialDouble-blindTreatment

Summary

This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.

Timeline

Start: 2026-03-10
Primary completion: 2028-11-01
Completion: 2028-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OCT-980	Small molecule	—	Oral

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

Summary

Timeline

Drugs

Indications